Utilisation : Ce produit est destiné uniquement à la recherche.
Toutes les informations sur les produits présentes sur ce site sont fournies à titre éducatif uniquement. Toute forme d’introduction dans le corps humain ou animal est strictement interdite par la loi. Ce produit doit être manipulé uniquement par des professionnels agréés et qualifiés. Il ne s’agit pas d’un médicament, d’un aliment ou d’un cosmétique et il ne doit pas être présenté, utilisé ou étiqueté comme tel.
IGF-1 LR3 1mg
Pendant notre changement d’emballage, vous pouvez recevoir des produits avec l’ancienne ou la nouvelle étiquette. La formulation, la pureté et la qualité restent exactement les mêmes, selon nos standards.
- Carte de crédit
- Virement bancaire (SEPA instantané)
- Virement bancaire (ACH)
- Wise
- Revolut
- Zelle
- Remitly
- Western Union
- Chime
- Autres
-25% sur tout – jusqu’au 31 octobre
25% sur les prix habituels, en remplacement des autres soldes. Cumulable uniquement avec la remise crypto.
Expédition le jour même pour les commandes aux États-Unis passées avant 12 h EST.
Voir la politique de livraison →Chaque lot est testé pour sa pureté, sa puissance et sa qualité.
Voir les résultats d’analyse →IGF-1 LR3 (Long Arg3-IGF-1) is a synthetic 83-amino-acid analogue of insulin-like growth factor 1, engineered with an N-terminal 13-amino-acid extension and an Arg3 substitution that together confer markedly reduced affinity for IGF-binding proteins (IGFBPs) and extended plasma half-life. These modifications preserve IGF-1 receptor (IGF-1R) agonist activity while reducing IGFBP sequestration, enabling sustained receptor engagement in preclinical research models.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
| Chemical Formula | C400H625N111O115S9 |
|---|---|
| Synonyms | Long R3-IGF-1, M9L22Y19H9, 143045-27-6, Long-(arg3)insulin-like growth factor-i |
| Molar Mass | 9,117.60 g/mol |
| CAS Number | 143045-27-6 |
| PubChem CID | N/A |
| Total Compound Content | 1 mg per vial |
| Shelf Life | 36 months |
Results refer to the tested sample. Check the batch and date in the report.
Why does IGF-1 LR3 have a longer half-life than native IGF-1?
Native IGF-1 is rapidly sequestered in circulation by IGF-binding proteins (IGFBPs 1–6), which extend its half-life but also restrict bioavailability. The Arg3 substitution and N-terminal 13-residue extension in IGF-1 LR3 reduce IGFBP affinity by approximately 1,000-fold, preventing this sequestration.
Without IGFBP binding, IGF-1 LR3 remains in free, receptor-accessible form for 56–72 hours — substantially longer than native IGF-1's 10–20-minute half-life when not IGFBP-bound.
Which intracellular signalling pathways does IGF-1 LR3 activate via IGF-1R?
IGF-1R is a receptor tyrosine kinase. Ligand binding drives receptor autophosphorylation, IRS-1/IRS-2 adapter recruitment, and activation of two primary downstream cascades: PI3K/Akt/mTOR (governing protein synthesis, glucose uptake, and cell survival) and MAPK/ERK (regulating cell proliferation and differentiation). Both pathways are fully engaged by IGF-1 LR3 at the IGF-1R, identical to native IGF-1.
What types of experimental programs are most suited to the IGF-1 LR3 10-vial KIT format?
The IGF-1 LR3 KIT format is particularly useful for longitudinal investigations, multi-arm experimental designs, concentration-response studies, receptor-signaling experiments, and pathway-characterization programs that require repeated compound preparation over extended periods.
The availability of multiple matched-batch vials supports consistent experimental conditions across separate study phases, treatment groups, and sampling timepoints. This makes the KIT format well-suited to research involving IGF-1 receptor signaling, PI3K/Akt/mTOR pathway analysis, MAPK/ERK pathway investigation, and comparative insulin-like growth factor pharmacology.
